This 2022 randomized, double-blind, placebo-controlled trial investigated the effects of alpha-lipoic acid (ALA) in reducing chemotherapy-induced toxicities in 64 women with breast cancer undergoing treatment with doxorubicin, cyclophosphamide, and paclitaxel. Patients were assigned to receive either ALA (600 mg/day) or placebo for six months. ALA significantly improved chemotherapy-induced peripheral neuropathy
